Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Monopar Therapeutics Inc (NQ: MNPR ) 2.430 -0.010 (-0.41%) Streaming Delayed Price Updated: 3:58 PM EDT, Sep 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Monopar Therapeutics Inc < Previous 1 2 3 4 5 6 Next > Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments May 11, 2023 Camsirubicin Phase 1b DoseEscalation Trial Enrolling 5th DoseLevel Cohort (650 mg/m2) MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study Results From Monopar Therapeutics Inc. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023 March 29, 2023 Via Benzinga 5 Analysts Have This to Say About Monopar Therapeutics March 28, 2023 Via Benzinga What's Going On With Monopar Therapeutics Shares Today? February 14, 2023 Via Benzinga Nasdaq Dips 90 Points; Walgreens Posts Upbeat Q2 Results March 28, 2023 U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 90 points on Tuesday. The Dow traded down 0.21% to 32,362.74 while the NASDAQ fell 0.77% to 11,678.39. The... Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session March 28, 2023 Via Benzinga Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 28, 2023 Gainers Via Benzinga Dow Rises 50 Points; Harmony Biosciences Shares Plunge March 28, 2023 U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 50 points on Tuesday. The Dow traded up 0.16% to 32,484.24 while the NASDAQ fell 0.75% to 11,681.12. The S&P 500, also... Via Benzinga Monopar Therapeutics Shelves Development Of Validive For Radiation Therapy-Related Complication March 28, 2023 Monopar Therapeutics Inc (NASDAQ: MNPR) completed a pre-specified interim analysis for its Validive Phase 2b/3 VOICE trial for the prevention of severe oral mucositis (SOM) in patients undergoing... Via Benzinga Monopar Therapeutics Shares Are Tumbling: What's Going On? March 28, 2023 Monopar Therapeutics Inc (NASDAQ: MNPR) shares are plunging in early trading Tuesday after the company announced it will discontinue the active development of Validive after being informed... Via Benzinga Why Is Alibaba (BABA) Stock Up 9% Today? March 28, 2023 Alibaba (BABA) stock is on the rise Tuesday after the company revealed plans to split up into six businesses and become a holding company. Via InvestorPlace Why Is WiSA Technologies (WISA) Stock Down 22% Today? March 28, 2023 WiSA Technologies (WISA) stock is falling on Tuesday but that's only after the company's shares underwent a rally yesterday. Via InvestorPlace Why Is Monopar Therapeutics (MNPR) Stock Down 47% Today? March 28, 2023 Monopar Therapeutics (MNPR) stock is taking a beating on Tuesday after the company revealed lackluster clinical trial results. Via InvestorPlace 12 Health Care Stocks Moving In Tuesday's Pre-Market Session March 28, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday March 28, 2023 We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! Via InvestorPlace Monopar to Present at the Jefferies Radiopharma Innovation Summit March 28, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis March 27, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday March 23, 2023 We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning! Via InvestorPlace Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments March 23, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session March 21, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday March 21, 2023 We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning! Via InvestorPlace 12 Health Care Stocks Moving In Thursday's Pre-Market Session March 16, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday March 16, 2023 It's time for another dive into the biggest pre-market stock movers as we go over all the latest news for Thursday morning! Via InvestorPlace Monopar to Present at the 35th Annual Roth Conference March 07, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday March 02, 2023 It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Thursday morning! Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday February 28, 2023 It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Monday! Via InvestorPlace Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket February 27, 2023 Gainers Lucira Health, Inc. (NASDAQ: LHDX) rose 228.5% to $0.46 in pre-market trading after the FDA authorized Lucira's over-the-counter at-home test to detect both influenza and COVID-19 viruses. Via Benzinga Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials February 27, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session February 22, 2023 Via Benzinga Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin February 14, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.